# Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

> **NCT01280565** · PHASE3 · TERMINATED · sponsor: **AB Science** · enrollment: 134 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01280565
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 134 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2020-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280565, "Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01280565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*